Clinical Trial Update: A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 1/2 clinical trial evaluating an oral VEGFR-2 tyrosine kinase inhibitor in combination with chemotherapy for lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Oral VEGFR-2 tyrosine kinase inhibitor (Pfizer study)

Snippet

Sponsor: Pfizer | Conditions: Lung Neoplasms | Phase 1, Phase 2 | Status: COMPLETED